Ali Daud, Alam Nawazish, Yasmin Farhat, Ali Sajid, Anwer Tarique, Alam Sarfaraz, Ahmad Sarfaraz
Departmentof Pharmacy Practice, National Institute of Pharmaceutical Education & Research, Hajipur, India.
Collegeof Pharmacy, Jazan University, Jazan, KSA.
Iran J Pharm Res. 2017 Spring;16(2):798-804.
The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational armwith the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer.Atotal of 60 patients were enrolled in the study.Out of 30 patients enrolledinarm-A (Gemcitabine withCisplatin) and 30 patients enrolledin arm-B (5-Flurouracilwith Cisplatin) for safety assessment. For the efficacy evaluation total of 16 patients enrolled which is equally divided in both arm.Total 150 cycles of chemotherapy were given to each arm of patients. Both armswere well balanced with respect to age, stage of disease and measurability.The overall response rate (ORR) was 62.5% in arm-A compared to 50% in arm-B (p = 0.34). Whereas 95% confidence interval (CI) for the efficacy was found 46.25-8.74%32.67-67.32% between arm-A and arm-B.The most prevalent toxicities were found anemia (p < 0.05), neutropenia (p < 0.05) leucopenia (p<0.05) and thrombocytopenia (p < 0.05) and it occurred at a higher rate in arm-B than in arm-A of various grades.There was no statistically significant efficacy & toxicity for gemcitabine and cisplatin with 5-flurouracil and cisplatin however there was an overall more benefit in arm-A patients than arm-B patients.
该研究旨在比较研究组中5-氟尿嘧啶与顺铂联合方案和吉西他滨与顺铂联合的对照方案治疗胆囊癌的安全性和疗效。共有60名患者参与了该研究。为进行安全性评估,30名患者入组A组(吉西他滨与顺铂联合),30名患者入组B组(5-氟尿嘧啶与顺铂联合)。为进行疗效评估,共入组16名患者,两组各半。每组患者均接受了150个周期的化疗。两组在年龄、疾病分期和可测量性方面平衡良好。A组的总缓解率(ORR)为62.5%,而B组为50%(p = 0.34)。A组和B组疗效的95%置信区间(CI)分别为46.25 - 8.74%和32.67 - 67.32%。最常见的毒性反应为贫血(p < 0.05)、中性粒细胞减少(p < 0.05)、白细胞减少(p < 0.05)和血小板减少(p < 0.05),且B组各等级毒性反应的发生率均高于A组。吉西他滨与顺铂联合方案和5-氟尿嘧啶与顺铂联合方案在疗效和毒性方面无统计学显著差异,但总体而言,A组患者比B组患者获益更多。